2014 readers choice results
Article updated: 5/8/2013 10:43 AM

Takeda to acquire Inviragen for $250 million

Buy this photo Buy this photo
Gallery Image

Deerfield-based Takeda Pharmaceutical Co. said its U.S. subsidiary, Takeda America Holdings, Inc., awill acquire biopharmaceutical company Inviragen for an estimated total of $250 million.

About this Article

Deerfield-based Takeda Pharmaceutical Co. said its U.S. subsidiary, Takeda America Holdings, Inc., awill acquire biopharmaceutical company Inviragen for an estimated total of $250 million. Takeda said it will make an upfront payment of $35 million, and future payments of up to $215 million that are linked to the progress of clinical development and achievement of key commercial milestones, according to a release.
Galleries by Category